CA3222484A1 - Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools - Google Patents

Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools Download PDF

Info

Publication number
CA3222484A1
CA3222484A1 CA3222484A CA3222484A CA3222484A1 CA 3222484 A1 CA3222484 A1 CA 3222484A1 CA 3222484 A CA3222484 A CA 3222484A CA 3222484 A CA3222484 A CA 3222484A CA 3222484 A1 CA3222484 A1 CA 3222484A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
prodrug
independently selected
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3222484A
Other languages
English (en)
French (fr)
Inventor
Daniel DIPIETRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zogenix Inc
Original Assignee
Zogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zogenix Inc filed Critical Zogenix Inc
Publication of CA3222484A1 publication Critical patent/CA3222484A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA3222484A 2021-06-18 2022-06-15 Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools Pending CA3222484A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163212468P 2021-06-18 2021-06-18
US63/212,468 2021-06-18
PCT/US2022/033654 WO2022266237A1 (en) 2021-06-18 2022-06-15 Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools

Publications (1)

Publication Number Publication Date
CA3222484A1 true CA3222484A1 (en) 2022-12-22

Family

ID=84526701

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3222484A Pending CA3222484A1 (en) 2021-06-18 2022-06-15 Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools

Country Status (9)

Country Link
US (2) US20230000890A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355336A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024522783A (cg-RX-API-DMAC7.html)
CN (1) CN117500510A (cg-RX-API-DMAC7.html)
AU (1) AU2022291783A1 (cg-RX-API-DMAC7.html)
CA (1) CA3222484A1 (cg-RX-API-DMAC7.html)
IL (1) IL309421A (cg-RX-API-DMAC7.html)
MX (1) MX2023014944A (cg-RX-API-DMAC7.html)
WO (1) WO2022266237A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022204555A1 (en) * 2021-03-26 2022-09-29 Zogenix Mds, Inc. Aqueous solutions containing purines and pyrimidines and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10292996B2 (en) * 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
WO2016205671A1 (en) * 2015-06-17 2016-12-22 The Trustees Of Columbia University In The City Of New York Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
EP3377512A4 (en) * 2015-11-16 2019-09-18 Ichorion Therapeutics, Inc. Nucleic Acid PRODRUGS
IL277725B2 (en) * 2018-04-12 2024-02-01 Modis Therapeutics Inc Pro-drugs of deoxynucleosides for the treatment of diseases resulting from an imbalance in the nucleotide reserves

Also Published As

Publication number Publication date
US20230000890A1 (en) 2023-01-05
WO2022266237A1 (en) 2022-12-22
CN117500510A (zh) 2024-02-02
EP4355336A1 (en) 2024-04-24
AU2022291783A1 (en) 2024-02-01
US20250049836A1 (en) 2025-02-13
IL309421A (en) 2024-02-01
JP2024522783A (ja) 2024-06-21
MX2023014944A (es) 2024-04-25
EP4355336A4 (en) 2025-05-07

Similar Documents

Publication Publication Date Title
US6875751B2 (en) 3′-prodrugs of 2′-deoxy-β-L-nucleosides
JP4639032B2 (ja) 2’−デオキシ−β−L−ヌクレオシドの3’−プロドラッグ
US8877731B2 (en) Azido nucleosides and nucleotide analogs
US12419901B2 (en) Prodrugs of deoxynucleosides for treatment of diseases caused by unbalanced nucleotide pools
CA2819041A1 (en) Cyclic nucleotide analogs
CN116726035A (zh) 用于包括线粒体dna耗竭综合症在内的由不平衡的核苷酸库引起的疾病的脱氧核苷疗法
US20230060544A1 (en) Treatment of mitochondrial diseases
WO2012078416A2 (en) Monophosphate prodrugs of dapd and analogs thereof
US20250049836A1 (en) Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools
Périgaud et al. The S-acyl-2-thioethyl pronucleotide approach applied to acyclovir: part I. Synthesis and in vitro anti-hepatitis B virus activity of bis (S-acyl-2-thioethyl) phosphotriester derivatives of acyclovir
US12465615B2 (en) Aqueous solutions containing purines and pyrimidines and uses thereof

Legal Events

Date Code Title Description
R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241213

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241213

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R125 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMMON REPRESENTATIVE APPOINTED

Effective date: 20250307

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250307

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260505

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260727

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728